First-Ever Blood Test Could Detect Deadly Heart Inflammation Within Hours

Myocarditis, or inflammation of the heart muscle, is a difficult condition to diagnose. Symptoms include a temperature, fatigue, chest pain and shortness of breath, which can all be easily mistaken for other conditions. The gold standard method for diagnosis is a heart biopsy, an expensive, invasive, and risky procedure which can sometimes still miss signs of the condition. It’s estimated that one young person dies suddenly every week in the UK due to previously undiagnosed myocarditis. Now, a team of researchers has discovered a molecular signal in the blood that could pave the way for the first blood test to be used for diagnosing myocarditis within as little as a year.

The discovery by researchers at Queen Mary University of London (London, UK) in a study funded by the British Heart Foundation (BHF, London, UK) could result in a quick and cheap way of diagnosing the condition, and help patients get lifesaving treatment earlier. The researchers found that the presence of T-cells – a type of white blood cell – expressing a molecule called cMet in the blood strongly indicates that a person has myocarditis. They say that cMet-expressing T cells levels could be detected through a routine blood test that could cost less than GBP 50 with results available within hours. The researchers hope that this finding will improve diagnosis of myocarditis and help people to get the treatment they need earlier, reducing the risk that they will develop life-threatening complications such as abnormal heart rhythms or heart failure.

In the study, researchers compared blood samples from several groups of patients, including 34 people with a final diagnosis of myocarditis. This showed that patients with myocarditis had significantly increased levels of T cells with cMet on their surface compared to other groups, including heart attack patients, and those with no medical condition. These findings add to the evidence that myocarditis is an autoimmune condition. The team found that cMet-expressing T cells become activated by molecules expressed by heart cells, producing an immune reaction against these cells that leads to inflammation of the heart muscle. The researchers also discovered that in mice, T cells with the cMet molecule seemed to have a role in driving the development of the condition. Blocking cMet with a widely available drug reduced the severity of their myocarditis. The team will investigate this finding further in future studies and hope it will help them to develop the first targeted treatment for myocarditis.

 “Early intervention is crucial when treating myocarditis as, in some cases, it can be only a matter of weeks between the onset of symptoms and development of heart failure. But without a diagnosis doctors can’t offer their patients the right treatment,” said Professor Federica Marelli-Berg, British Heart Foundation Professor of Cardiovascular Immunology. “We think that this test for myocarditis could be a simple addition to the routine blood tests ordered in doctors' surgeries. When viewed in combination with symptoms, the results could allow GPs to easily determine whether their patients have myocarditis. While we still need to confirm these findings in a larger study, we’re hopeful that it won’t be long until this blood test is in regular use.”

“Myocarditis is a notoriously tricky condition to diagnose and sadly some patients will suffer irreversible damage to their hearts because of the lack of accessible diagnostic tests,” added Professor Sir Nilesh Samani, Medical Director at the British Heart Foundation. “This blood test could revolutionize the way we diagnose myocarditis, allowing doctors to step in at a much earlier stage to offer treatment and support. It would also reduce the need for the risky, invasive tests currently used, saving the NHS time and money and freeing up vital resources.”

Related Links:
Queen Mary University of London 
BHF

Visit expo >

Gold Member

Serological Pipet Controller

PIPETBOY GENIUS

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Amoebiasis Test

ELI.H.A Amoeba

New

Calprotectin Assay

Fecal Calprotectin ELISA